MEREO BIOPHARMA GROUP PLC Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five
MEREO BIOPHARMA GROUP PLC (MREO) had Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five of $0 as of 2024-12-31, per its 10-K filed 2025-03-26.
Financial Statements › Notes › Leases › Lessee, Operating Lease, Liability, to be Paid, Rolling Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive · last filed 2025-03-26
- 2024-12-31: Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five $0.00.
- 2023-12-31: Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five $0.00.
| Period end | Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-26 |
| 2023-12-31 | $0.00 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |